+91 80 2808 2808

Biocon is neither Evaluating Any Divestment Options for Its APIs Business nor Consulting any Bankers

  • Posted by: BIOCON


in response to media article on ‘Biocon Weighs Sale of API Business’

Bengaluru, Karnataka, India, December 15, 2023

“The Company is neither evaluating any divestment options for its APIs business nor consulting any bankers for this.

The story published in Economic Times today, with the headline, “Biocon Weighs Sale of $1.5.b Generic API Biz” is baseless and speculative.

The API business is a strategic business segment of Biocon Limited and a key growth driver for the Company’s small molecules business.

Biocon continues to strengthen this business and has an ongoing investment of over half a billion dollars in CAPEX and R&D.

The Company has a strong pipeline of niche fermentation-based APIs, peptides and high potent API products for the near- and long-term growth of its integrated APIs and Generic Formulations business.” – Company Spokesperson

For more information:

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>